Nuvectis Pharma, Inc.
NVCT
$8.76
-$0.04-0.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.98% | -17.81% | -18.79% | 14.66% | -50.45% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.30% | -15.83% | 26.54% | 19.89% | -1.55% |
| Change in Net Operating Assets | 23.36% | 22.25% | 688.57% | -107.95% | 347.80% |
| Cash from Operations | 11.57% | -33.47% | 19.33% | -69.33% | -2.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.17% | 2,106.84% | -96.34% | 324.94% | 162.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 79.85% | -27.99% | 75.41% | -942.74% | -148.00% |
| Cash from Financing | -98.74% | 4,340.20% | -98.09% | 304.94% | 162.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.03% | 381.63% | -127.10% | 730.72% | 244.03% |